StockData
Dare Bioscience, Inc. logo

Dare Bioscience, Inc. (DARE) stock

DARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$0.58−0.07 (-11.13%)

Close on Nov 16, 2026Market cap $8.93MP/E –Yield –

Dare Bioscience operating margin

Operating margin is operating income as a percentage of revenue.

Dare Bioscience's operating margin for the twelve months ending Jun 30, 2026 was -813.4%. For fiscal 2025 it was -1315.5%, against -239692.2% the year before. The highest annual figure on record is -82.3% in fiscal 2016.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-1315.5%+238376.7
FY2024Dec 31, 2024-239692.2%−238590.3
FY2023Dec 31, 2023-1101.9%−788.0
FY2022Dec 31, 2022-313.9%−231.5
FY2016Dec 31, 2016-82.3%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-1582.5%+16434.2
Q1 FY2026Mar 31, 2026-1967.1%+9261.6
Q4 FY2025Dec 31, 2025-143.7%+32655.4
Q3 FY2025Sep 30, 2025-162340.8%−97596.9
Q1 FY2025Mar 31, 2025-18016.7%−17730.7
Q3 FY2024Sep 30, 2024-11228.7%−10389.0
Q2 FY2024Jun 30, 2024-32799.1%−32803.0
Q1 FY2024Mar 31, 2024-64743.9%−64669.1
Q4 FY2023Dec 31, 2023-286.1%−266.9
Q3 FY2023Sep 30, 2023-839.6%−815.0
Q2 FY2022Jun 30, 20223.8%–
Q2 FY2017Jun 30, 2017-74.7%–
Q1 FY2017Mar 31, 2017-19.2%–
Q4 FY2016Dec 31, 2016-24.6%–

More Dare Bioscience figures

See a number that looks wrong?